Sorry : more to add:
“The reporting of key study findings from the nine-month chronic monkey toxicology study in 1H’24 is due around the same time as the results from the blinded phase of the ATL1102 Phase IIb DMD clinical study are expected, which could then allow the Company to share with FDA and other regulatory bodies a compelling data package of clinical and toxicology study results for potential discussions on accelerated regulatory pathways to registration. In addition, and subject to it meeting the eligibility criteria, the Company may also be in a position to receive a future Pediatric Review Voucher (PRV)2,3. In recent years the price paid for PRVs has ranged between US$95 million and US$110 million4”
Sam: Please spare us more of I said this and I said that
Do you really think CG would not have done possible situations with the FDA and EMA before signing off on the Anp announcement ..?
Sorry : more to add:“The reporting of key study findings from...
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
